Clinical Trial

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Study acronym: REZILIENT1
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
CLN-081-001 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to characterize the safety, determine the recommended Phase 2 dose (RP2D), and evaluate efficacy.
Protocol Amendment History 40 amendments
This ClinicalTrials.gov record has been amended 40 times since 2019-07-25; most recent amendment 2026-06-15.
Status change: Recruiting → Active, Not Recruiting 2024-09-15
Status change: Not Yet Recruiting → Recruiting 2019-10-20
Trial Details
NCT Number NCT04036682
Lead Sponsor Cullinan Therapeutics Inc.
Collaborators: Taiho Oncology, Inc.
Conditions Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
Enrollment 284 participants
Start Date 2019-10-31
Primary Completion 2025-10-13 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-17